Association of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and neurogenesis: a systematic review
Acta Neuropsychiatrica · 2025
DOI: 10.1017/neu.2025.4 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Acta Neuropsychiatrica, 2025. Verfasst von Hezekiah C T Au und 11 weiteren Autor:innen. Beteiligte Einrichtung: Brain and Cognition Discovery Foundation, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Neurogenesis, Glucagon-Like Peptide-1 Receptor Agonists, Glucagon-Like Peptide 1. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
Glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-1 receptor agonist (GLP-1 RA) administration has been associated with neuroproliferative effects and modulatory effects in neuronal pathways. Herein, we conducted a comprehensive synthesis of the effects of GLP-1 and GLP-1 RAs on neurogenesis.
Methods
We examined studies that investigate changes in neurogenesis mediated by GLP-1 and GLP-1 RA administration in both human and animal populations. Relevant articles were retrieved through OVID (MedLine, Embase, AMED, PsychINFO, JBI EBP Database), PubMed, and Web of Science from database inception to July 2nd. Primary studies investigating the role of GLP-1 and GLP-1 RAs on neurogenesis were included for analysis.
Results
GLP-1 and GLP-1 RAs (i.e. exenatide, geniposide, liraglutide, lixisenatide, and semaglutide), increased neurogenesis within the dentate gyrus, hippocampus, olfactory bulb, and the medial striatum in animal models. Additionally, GLP-1 and GLP-1 RAs were associated with modulating changes in multiple apoptotic pathways and upregulating survival pathways.
Discussion
GLP-1 and GLP-1 RAs are positively associated with neurogenesis. This effect may have translational implications insofar as disparate mental disorders that are characterised by neurogenesis defects (e.g. depressive disorders and neurocognitive disorders) may be benefitted by these agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Brain and Cognition Discovery Foundation, Toronto, Ontario, Canada.
- Mood Disorder Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada.
- Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.
- Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.
- Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
- Department of Psychiatry, University of Toronto, Toronto, Canada.
ORCID-Profile: Hezekiah C T Au, Yang Jing Zheng, Roger S McIntyre
Zitieren
APA
Au, H. C. T., Zheng, Y. J., Le, G. H., Wong, S., Teopiz, K. M., Kwan, A. T. H., Gill, H., Badulescu, S., Valentino, K., Rosenblat, J. D., Mansur, R. B., & McIntyre, R. S. (2025). Association of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and neurogenesis: a systematic review. Acta Neuropsychiatrica. https://doi.org/10.1017/neu.2025.4
Vancouver
Au HCT, Zheng YJ, Le GH, Wong S, Teopiz KM, Kwan ATH, et al. Association of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and neurogenesis: a systematic review. Acta Neuropsychiatrica. 2025. doi:10.1017/neu.2025.4
BibTeX
@article{Au2025,
author = {Au, Hezekiah C T and Zheng, Yang Jing and Le, Gia Han and Wong, Sabrina and Teopiz, Kayla M and Kwan, Angela T H and Gill, Hartej and Badulescu, Sebastian and Valentino, Kyle and Rosenblat, Joshua D and Mansur, Rodrigo B and McIntyre, Roger S},
title = {Association of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and neurogenesis: a systematic review},
journal = {Acta Neuropsychiatrica},
year = {2025},
doi = {10.1017/neu.2025.4}
}
EUVIMED